We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+11.58%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$904M
AUM Growth
+$113M
Cap. Flow
+$79M
Cap. Flow %
8.74%
Top 10 Hldgs %
30.09%
Holding
103
New
13
Increased
46
Reduced
23
Closed
11

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$14.7M
2
ABBV icon
AbbVie
ABBV
+$12.4M
3
UNH icon
UnitedHealth
UNH
+$9.71M
4
AXSM icon
Axsome Therapeutics
AXSM
+$9.24M
5
PRCT icon
Procept Biorobotics
PRCT
+$9.13M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$13.9M
2
THC icon
Tenet Healthcare
THC
+$13.8M
3
HCA icon
HCA Healthcare
HCA
+$11.4M
4
VRNA
Verona Pharma
VRNA
+$10.1M
5
GILD icon
Gilead Sciences
GILD
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
26
Cytokinetics
CYTK
$10.5B
$14M 1.55%
255,250
+151,000
+145% +$6.22M
PRCT icon
27
Procept Biorobotics
PRCT
$1.24B
$13.9M 1.54%
390,000
+200,000
+105% +$9.13M
CI icon
28
Cigna
CI
$73.6B
$13.4M 1.48%
46,500
+14,500
+45% +$4.29M
ABT icon
29
Abbott
ABT
$188B
$13.2M 1.46%
98,500
+40,000
+68% +$5.25M
JAZZ icon
30
Jazz Pharmaceuticals
JAZZ
$16.7B
$12.5M 1.39%
95,030
-14,000
-13% -$1.68M
EW icon
31
Edwards Lifesciences
EW
$53B
$12.1M 1.33%
155,000
+100,000
+182% +$7.81M
THC icon
32
Tenet Healthcare
THC
$20.9B
$11.9M 1.31%
58,429
-78,000
-57% -$13.8M
AKRO
33
DELISTED
Akero Therapeutics
AKRO
$10.9M 1.21%
230,600
+33,000
+17% +$1.6M
ALGN icon
34
Align Technology
ALGN
$12.5B
$10.4M 1.15%
83,000
+16,500
+25% +$2.58M
BMRN icon
35
BioMarin Pharmaceuticals
BMRN
$13.3B
$10.1M 1.12%
186,650
+37,000
+25% +$2.12M
DOCS icon
36
Doximity
DOCS
$4.57B
$9.95M 1.1%
136,000
+115,000
+548% +$7.5M
RPRX icon
37
Royalty Pharma
RPRX
$25.8B
$9.12M 1.01%
258,500
-85,500
-25% -$3.1M
GILD icon
38
Gilead Sciences
GILD
$165B
$8.9M 0.98%
80,150
-88,000
-52% -$10M
SNDX icon
39
Syndax Pharmaceuticals
SNDX
$1.82B
$8.83M 0.98%
574,000
– –
MDGL icon
40
Madrigal Pharmaceuticals
MDGL
$11.9B
$8.37M 0.93%
+18,250
New +$6.81M
BIIB icon
41
Biogen
BIIB
$30.6B
$7.7M 0.85%
55,000
+43,000
+358% +$5.81M
DVAX
42
DELISTED
Dynavax Technologies
DVAX
$7.67M 0.85%
772,000
+207,000
+37% +$2.15M
ADPT icon
43
Adaptive Biotechnologies
ADPT
$4.05B
$7.41M 0.82%
+495,000
New +$6.03M
ELV icon
44
Elevance Health
ELV
$86.2B
$7.27M 0.8%
22,500
-22,150
-50% -$6.89M
DNTH icon
45
Dianthus Therapeutics
DNTH
$6.25B
$6.83M 0.76%
173,627
+47,000
+37% +$1.2M
MLYS icon
46
Mineralys Therapeutics
MLYS
$2.41B
$6.26M 0.69%
+165,000
New +$3.57M
CNC icon
47
Centene
CNC
$32.9B
$6.07M 0.67%
170,000
+70,243
+70% +$2.12M
STOK icon
48
Stoke Therapeutics
STOK
$2.08B
$5.88M 0.65%
+250,000
New +$4.28M
VKTX icon
49
Viking Therapeutics
VKTX
$4.02B
$5.68M 0.63%
216,288
+131,288
+154% +$3.92M
AVR
50
Anteris Technologies
AVR
$872M
$5.63M 0.62%
1,250,763
– –
1
2
3 4 5

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2025 Portfolio in Review

As of Q3 2025, Rhenman & Partners Asset Management held 103 positions worth $904M, up 14% from $791M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rhenman & Partners Asset Management deployed $79M of net new capital in Q3 2025, opening 13 new positions and adding to 46 existing holdings. Its largest new stake was Madrigal Pharmaceuticals: 18,250 shares worth $8.37M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Tenet Healthcare, an estimated $13.8M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2025 buy was Madrigal Pharmaceuticals: 18,250 shares worth $8.37M.
  • Rhenman & Partners Asset Management added most to Boston Scientific in Q3 2025, an estimated $14.7M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2025 reduction was Tenet Healthcare, cutting an estimated $13.8M.
  • Rhenman & Partners Asset Management fully exited DexCom in Q3 2025, selling an estimated $13.9M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 30% of its $904M portfolio in Q3 2025.
  • Rhenman & Partners Asset Management opened 13 new positions and closed 11 in Q3 2025.
  • Rhenman & Partners Asset Management's portfolio value rose 14% quarter-over-quarter to $904M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.